Wells Fargo & Company Protagonist Therapeutics, Inc Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Wells Fargo & Company holds 29,373 shares of PTGX stock, worth $1.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,373

Previous 30,190 2.71%

Holding current value

$1.36 Million

Previous $1.05 Million 26.2%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$33.72 - $47.33 $27,549 - $38,668	-817 Reduced 2.71%	29,373 $1.32 Million
Q2 2024 Aug 13, 2024	BUY	$24.66 - $34.8 $9,790 - $13,815	397 Added 1.33%	30,190 $1.05 Million
Q1 2024 May 10, 2024	BUY	$21.79 - $32.15 $297,128 - $438,397	13,636 Added 84.4%	29,793 $861,000
Q4 2023 Feb 09, 2024	SELL	$14.05 - $23.44 $848,718 - $1.42 Million	-60,407 Reduced 78.9%	16,157 $370,000
Q3 2023 Nov 13, 2023	BUY	$16.68 - $23.66 $91,956 - $130,437	5,513 Added 7.76%	76,564 $1.28 Million
Q2 2023 Aug 15, 2023	BUY	$18.02 - $29.36 $668,307 - $1.09 Million	37,087 Added 109.2%	71,051 $1.96 Million
Q1 2023 May 12, 2023	BUY	$10.78 - $25.38 $365,733 - $861,067	33,927 Added 91694.59%	33,964 $781,000
Q4 2022 Feb 13, 2023	SELL	$7.36 - $11.17 $16,979 - $25,769	-2,307 Reduced 98.42%	37 $0
Q3 2022 Nov 14, 2022	SELL	$7.86 - $11.71 $25,788 - $38,420	-3,281 Reduced 58.33%	2,344 $19,000
Q2 2022 Aug 12, 2022	SELL	$7.06 - $25.52 $143,981 - $520,454	-20,394 Reduced 78.38%	5,625 $44,000
Q1 2022 May 16, 2022	SELL	$23.34 - $36.08 $334,672 - $517,351	-14,339 Reduced 35.53%	26,019 $616,000
Q4 2021 Feb 14, 2022	SELL	$17.63 - $37.1 $323,880 - $681,564	-18,371 Reduced 31.28%	40,358 $1.38 Million
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $371,807 - $1.43 Million	28,711 Added 95.65%	58,729 $1.04 Million
Q2 2021 Aug 16, 2021	SELL	$25.57 - $44.88 $215,222 - $377,754	-8,417 Reduced 21.9%	30,018 $1.35 Million
Q1 2021 May 13, 2021	SELL	$19.02 - $31.15 $667,525 - $1.09 Million	-35,096 Reduced 47.73%	38,435 $995,000
Q4 2020 Feb 09, 2021	BUY	$18.49 - $25.13 $874,336 - $1.19 Million	47,287 Added 180.18%	73,531 $1.48 Million
Q3 2020 Nov 05, 2020	BUY	$15.19 - $22.4 $171,267 - $252,559	11,275 Added 75.32%	26,244 $514,000
Q2 2020 Aug 13, 2020	SELL	$6.19 - $18.84 $207,835 - $632,571	-33,576 Reduced 69.16%	14,969 $265,000
Q1 2020 May 14, 2020	BUY	$5.4 - $9.22 $262,143 - $447,584	48,545 New	48,545 $343,000

Others Institutions Holding PTGX

# of Institutions

247

Shares Held

56.4M

Call Options Held

76.3K

Put Options Held

114K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.28B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Protagonist Therapeutics, Inc Transaction History